Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, significantly reduces body weight and improves glycemic control in patients with type 2 diabetes compared to placebo and other active comparators.
If you have type 2 diabetes, tirzepatide is a once-weekly injection that can significantly lower your blood sugar and help you lose weight. It works by mimicking hormones that regulate blood sugar and appetite. While it can cause stomach issues like nausea, these often improve over time. It is more effective than some other common diabetes medications in lowering blood sugar and reducing weight.
Tirzepatide improves glycemic control compared to baseline, placebo, and active comparators. It is also associated with weight reduction and an improvement in some, but not all, dyslipidemia, cardiovascular risk, and nonalcoholic steatohepatitis (NASH) biomarkers.
Why this rating
The review synthesizes data from multiple phase II and III randomized controlled trials (RCTs), including the SURPASS and SURMOUNT programs.
Source
Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy
Lina Naseralallah et al. · Expert Opinion on Pharmacotherapy · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →